Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
King's College London Bayer |
---|---|
Information provided by: | King's College London |
ClinicalTrials.gov Identifier: | NCT00794859 |
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will also be explored with PET scans before and during treatment.
Condition | Intervention | Phase |
---|---|---|
Mesothelioma |
Drug: Sorafenib |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-Based Chemotherapy |
Estimated Enrollment: | 54 |
Study Start Date: | October 2008 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:
Exclusion Criteria:
Contact: James Spicer, MRCP PhD | +44 20 7188 4260 | james.spicer@kcl.ac.uk |
United Kingdom | |
Guy's and St Thomas' NHS Foundation Trust | Recruiting |
London, United Kingdom, SE1 9RT | |
Principal Investigator: James Spicer, MRCP, PhD |
Principal Investigator: | James Spicer, MRCP, PhD | King's College London |
Responsible Party: | King's College London ( James Spicer ) |
Study ID Numbers: | 2007-005091-13 |
Study First Received: | November 19, 2008 |
Last Updated: | November 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00794859 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Mesothelioma Sorafenib Adenoma Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Mesothelial |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |